Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amarin (fish oil supplement) meets all endpoint, stock up from $8 and change, to $16. Could Ariad receive like news and achieve the same share price increase? Stay tuned..
Don, you are faster on the keyboard than me..
This don't feel like I'm living next to Ward, June, Wally, and the Beav..
exwannabe, trust me, in five years, Dr. Clackson will President of R&D at Ariad, or will be President of R&D of another Biotech firm, or retired on his own island in the Carribean. I hope it is the latter......
Sorry BTH, if you don't know the difference between what makes a great CEO and what makes a great Scientist, I can't help you.. You have to understand the basics, sport..
After listening to Clackson many, many times now, I can almost assure you that he is not Presidential or CEO material. Listen to him, please. He is one of the most humble, honest scientist that you ever want to meet. And I will meet him some day, I'm sure.. However, I'm VERY pleased that Harvey promoted him to President of R&D a few months back..
From Harvey's presentation today, what was clear, is that there were MANY questions on the results of the Rida trial. There were many individuals that were questioning Harvey on if the Rida results were robust enough for FDA approval. I really think this is holding the stock back. (Even though we are up 60%)
Unfortunately, another EU country announced today that they will be looking now for an EU handout.. The market is acting again like it is March 2000, and Ariad will be affected as well. We are going to have a BIG correction VERY soon... IMHO..
To look at any stock, especially Ariad, back in 2000, when it was $48 per share and claim a rational relationship TA wise is utterly, plain stupid. Any stock over the last 100 years that has a move like that, you simply throw it out.. it is in the 6th Bollinger band..
OK, just push it under the rug like you normally do... It's just not there.
Here is the chart from 2004 to April 5, 2011. What you said is untrue.. You really need to look before you post. It's a small biotech for crying out loud..
http://finance.yahoo.com/echarts?s=ARIA+Interactive#chart2:symbol=aria;range=20040102,20110405;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on
The 2004 share price of Ariad will have no bearing on the technical analysis of Ariad today.. It's a start up biotech, for heavens sakes..
It looks like we have a healthy pull back today..
Well, mouse models are clearly not the same as CML patients, so we will have to see how Mr. Market values this. '113 WILL be dosing patients by the middle of the year, so I would throw that into your pricing model before the new pathway for Pona compound. Looks like the mo-mo continues with $8.50's early this AM likly..
This is the type of response Merck would receive from Harvey and the board of directors (remember, their his):
http://dealbook.nytimes.com/2011/04/05/cephalon-rejects-valeants-5-7-billion-takeover-bid/?partner=yahoofinance
I think Don's note above (the sticky note at the top) that defines the events potentially scheduled ahead of us, and his comments that with all the events ahead of us, we may have PR every 6 weeks or so, this may keep a good bid under Ariad.. In any event, it should be an interesting 15 months..
Oh, BTH, how quickly we (you) forget. Cory of JPM has been all over this stock when it was $6.25 in the middle of March (just a few days ago, really). Go to the CNBC archives and you can watch his video. Just saw it again today on my iPhone..
So what is it worth? I would find it hard to believe that a CEO would take it to his board north of $3 billion, or $24 per share. Longer term, it's worth more than that.
This (Ariad Pharma) is starting to have the look, taste, and feel of DNDN and HGSI...
WE got what i was looking for.. PR this am.
Wouldn't you expect that we will have an early morning press release on this before AACR? After all, it is a new pathway for Ponatinib:
"Ponatinib (AP24534), a potent pan-FGFR inhibitor with
activity in multiple FGFR-driven cancer models," on Tuesday, April 5th
CAMBRIDGE, Mass., Mar 29, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new
preclinical data on ponatinib,
the company's investigational multi-targeted tyrosine kinase inhibitor,
will be presented at the American Association for Cancer Research (AACR)
Annual Meeting to be held April 2-6, 2011 in Orlando, FL.
ARIAD scientist Joseph M. Gozgit, Ph.D., will present the poster
entitled, "Ponatinib (AP24534), a potent pan-FGFR inhibitor with
activity in multiple FGFR-driven cancer models," on Tuesday, April 5,
2011 between 8:00 am and 12:00 pm. The ARIAD poster will be presented
during the session titled "Experimental and Molecular Therapeutics 25"
in Exhibit Hall A4-C, Poster Section 28, Abstract Number 3560.
About ARIAD
The more and more I examine Ariad as a longer term investment due to all the indications that their three compound appear to be able to target, the more I see this as having an above $30 print in the future.. Is this a new biotech franchise in the making??
Last week, in 5 days, we went up $.70, or 9.86% ($7.10 to $7.80). Let's see what Mr. Market has in store for us this week..
This is welcomed news for me with my Ariad investment: Medicare to pay for $93,000 treatment that extends life approx. 4 months
http://finance.yahoo.com/news/Medicare-to-pay-for-93000-apf-2472968382.html?x=0&sec=topStories&pos=7&asset=&ccode=
Harvey, very shrewedly, said selling in the Japan market was not prudent, at this time.. He left it open for the future sales activities. Does this mean that Ariad will just partner Pona for CML/ future AML in Japan, and will look to develop a sales force for all the other indications (breast, other solid tumors, ect.) with Pona in Japan? And China?
I just love the confidence that Harvey has.. I bet Ms. Cantor is fielding the question now everyday, "Is Ariad up for sale??". Harvey just feeds the fire....
For example, asking Merck's board to approve a purchase of Ariad from today's levels ($7.30 area) to $34 would be impossible, however, letting Ariad blossom to the $13- $15 area then do a deal at $22 -$28 is a better possibility..
BTH, I stand corrected..thank you.. I didn't see that post..must of missed it..
Don, can we add what Harvey said, "the release of information on new indications for all three of their compounds. Today, we just had the release for the pan-FGFR inhibitor for Pona, which is one. '113 will have one beyond NSCLC, and Rida will have another..
Bio-tec-hedge, what is new is potent pan-FGFR inhibitor . I don't believe your "discovery" engine found that.